Scholarlink

<p>Current biomarkers for Parkinson’s disease (PD) diagnosis, including imaging tracers, α-synuclein seeding assays, proteomic markers, and metabolomic signatures, are often limited by invasiveness, cost, scalability, or insufficient reproducibility. Circulating microRNAs (miRNAs) are attractive minimally invasive biomarkers because they are mechanistically linked to disease-associated pathways and remain stable in biofluids. However, the clinical translation of miRNA biomarkers has been hindered by multistep workflows and analytical variability arising from adapter ligation, reverse transcription, amplification drift, and cross-platform inconsistency in qRT-PCR, sequencing, and hybridization-based assays. To address these limitations, we developed XENO-Q, a rapid three-step platform that enables bias-minimized miRNA quantification through target-selective synthesis, in which only sensor-confirmed miRNAs are converted into amplifiable chimera products. XENO-Q enables linear quantification across several orders of magnitude with femtomolar sensitivity and high reproducibility while maintaining compatibility with qRT-PCR, ddPCR, and nanopore sequencing workflows. As a demonstration of clinical applicability, XENO-Q identified a two-marker circulating miRNA signature that accurately distinguished PD from other neurodegenerative conditions. These findings establish XENO-Q as a scalable and clinically translatable framework for next-generation miRNA diagnostics beyond Parkinson’s disease.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a rapid and simple Xeno Nucleic Acid (XNA) sensor-based microRNA detection platform for Parkinson’s disease diagnostics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Mi Young Byun,
  • Moon Young Ryu,
  • Seok Jong Chung,
  • Bora Lee,
  • Jong Ryeol Oh,
  • Jin Kyu Woo,
  • Jin Young Shin,
  • Min Kyun Han,
  • Oh Young Bang,
  • Yun Joong Kim,
  • Ming-Che Kuo,
  • Hsiang-Hsuan Lin-Wang,
  • Rudy-Meei Wu,
  • Shau-Ping Lin,
  • Seok Keun Cho,
  • Phil Hyu Lee,
  • Seong Wook Yang

摘要

Current biomarkers for Parkinson’s disease (PD) diagnosis, including imaging tracers, α-synuclein seeding assays, proteomic markers, and metabolomic signatures, are often limited by invasiveness, cost, scalability, or insufficient reproducibility. Circulating microRNAs (miRNAs) are attractive minimally invasive biomarkers because they are mechanistically linked to disease-associated pathways and remain stable in biofluids. However, the clinical translation of miRNA biomarkers has been hindered by multistep workflows and analytical variability arising from adapter ligation, reverse transcription, amplification drift, and cross-platform inconsistency in qRT-PCR, sequencing, and hybridization-based assays. To address these limitations, we developed XENO-Q, a rapid three-step platform that enables bias-minimized miRNA quantification through target-selective synthesis, in which only sensor-confirmed miRNAs are converted into amplifiable chimera products. XENO-Q enables linear quantification across several orders of magnitude with femtomolar sensitivity and high reproducibility while maintaining compatibility with qRT-PCR, ddPCR, and nanopore sequencing workflows. As a demonstration of clinical applicability, XENO-Q identified a two-marker circulating miRNA signature that accurately distinguished PD from other neurodegenerative conditions. These findings establish XENO-Q as a scalable and clinically translatable framework for next-generation miRNA diagnostics beyond Parkinson’s disease.

Graphical abstract